Cocrystal Pharma

Cocrystal Pharma

Biotechnology, N Creek Pkwy, Bothell, , 98011, Washington, 19805, United States, 11-50 Employees

cocrystalpharma.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 42********

Who is COCRYSTAL PHARMA

Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of COVID-19 a...

Read More

map
  • 19805 N Creek Pkwy, Bothell, Washington, 98011, United States Headquarters: 19805 N Creek Pkwy, Bothell, Washington, 98011, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from COCRYSTAL PHARMA

Cocrystal Pharma Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Cocrystal Pharma

Answer: Cocrystal Pharma's headquarters are located at N Creek Pkwy, Bothell, , 98011, Washington, 19805, United States

Answer: Cocrystal Pharma's phone number is 42********

Answer: Cocrystal Pharma's official website is https://cocrystalpharma.com

Answer: Cocrystal Pharma's revenue is $1 Million to $5 Million

Answer: Cocrystal Pharma's SIC: 2834

Answer: Cocrystal Pharma's NAICS: 325412

Answer: Cocrystal Pharma has 11-50 employees

Answer: Cocrystal Pharma is in Biotechnology

Answer: Cocrystal Pharma contact info: Phone number: 42******** Website: https://cocrystalpharma.com

Answer: Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of COVID-19 and other coronaviruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The company is enrolling subjects in a Phase 1 trial with an antiviral candidate for pandemic and seasonal influenza A, and plans to initiate COVID-19 clinical trials in 2022 with an orally administered and inhalation/pulmonary delivered antiviral candidates.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access